TROG 99.05 - Lung Tumour Volume - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

Tumour Volume as an Independent Prognosis Factor in Patients with Non-Small Cell Lung Cancer: A Protocol for a Progressive Database

Primary Sponsor

Clinical Trial Registration

Registration Link

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof

Register for the 2025 ASM

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Tumour Volume as an Independent Prognosis Factor in Patients with Non-Small Cell Lung Cancer: A Protocol for a Progressive Database

TROG 99.06 – Bladder (Phase II)

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

Related Post

Extended follow-up of TROG 99.03 lymphoma trial published

Meet TROG President: A/Prof Puma Sandaresan

Register for the 2025 ASM

TROG 99.05 – Lung Tumour Volume

Tumour Volume as an Independent Prognosis Factor in Patients with Non-Small Cell Lung Cancer: A Protocol for a Progressive Database

TROG 99.06 – Bladder (Phase II)

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

Related Post

Extended follow-up of TROG 99.03 lymphoma trial published

Meet TROG President: A/Prof Puma Sandaresan

Register for the 2025 ASM